|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Belotecan
Description of Belotecan: Belotecan hydrochloride is the hydrochloride salt of
the semi-synthetic camptothecin analogue belotecan with potential
antitumor activity. Belotecan binds to and inhibits the activity of
topoisomerase I, stabilizing the cleavable complex of topoisomerase
I-DNA, which inhibits the religation of single-stranded DNA breaks
generated by topoisomerase I; lethal double-stranded DNA breaks occur
when the topoisomerase I-DNA complex is encountered by the DNA
replication machinery, DNA replication is disrupted, and the tumor cell
undergoes apoptosis. Topoisomerase I is an enzyme that mediates
reversible single-strand breaks in DNA during DNA replication. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer:
Chong
Keun Dang Corp, Seoul, Korea;
|
MedKoo Code#:
200461
|
|
Name:
Belotecan
|
|
CAS#:
256411-32-2
Synonym: Camtobell®,
CKD602.
IUPAC/Chemical name:
(4S)-4-Ethyl-4-hydroxy-11-(2-(isopropylamino)ethyl)-1,12-dihydro-14H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H)-dione
hydrochloride
|
|
Chemical structure:
|
Theoretical analysis
|
|
|
Belotecan (free base form)
Chemical Formula: C25H27N3O4
Exact Mass: 433.20016
Molecular Weight: 433.5
Elemental Analysis: C, 69.27; H, 6.28; N,
9.69; O, 14.76
Belotecan hydrochloride:
Chemical Formula: C25H28ClN3O4
Molecular Weight: 469.96
Elemental Analysis: C, 63.89; H, 6.01; Cl,
7.54; N, 8.94; O, 13.62
|
|
Availability and price:
Belotecan is available through custom synthesis.
To inquire the quotation and lead time of custom synthesis for this agent, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
1: Kim HS, Park NH, Kang S, Seo SS, Chung HH, Kim JW,
Song YS, Kang SB. Comparison of the efficacy between topotecan- and
belotecan-, a new camptothecin analog, based chemotherapies for
recurrent epithelial ovarian cancer: a single institutional experience.
J Obstet Gynaecol Res. 2010 Feb;36(1):86-93. PubMed PMID: 20178532.
2: Jeong J, Cho BC, Sohn JH, Choi HJ, Kim SH, Lee YJ, Jung MK, Shin SJ,
Park MS, Kim SK, Chang J, Kim JH. Belotecan for relapsing small-cell
lung cancer patients initially treated with an irinotecan-containing
chemotherapy: A phase II trial. Lung Cancer. 2010 Mar 16. [Epub ahead of
print] PubMed PMID: 20138389.
3: Lee DH, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC,
Ryoo BY, Yang SH. Multicenter phase 2 study of belotecan, a new
camptothecin analog, and cisplatin for chemotherapy-naive patients with
extensive-disease small cell lung cancer. Cancer. 2010 Jan
1;116(1):132-6. Erratum in: Cancer. 2010 Jan 15;116(2):540. PubMed PMID:
19904804.
4: Nam EJ, Kim JW, Kim JH, Kim S, Kim SW, Jang SY, Lee DW, Jung YW, Kim
YT. Efficacy and Toxicity of Belotecan With and Without Cisplatin in
Patients With Recurrent Ovarian Cancer. Am J Clin Oncol. 2009 Sep 10. [Epub
ahead of print] PubMed PMID: 19745693.
5: Kim SJ, Kim JS, Kim SC, Kim YK, Kim YK, Kang JY, Yoon HK, Song JS,
Lee SH, Moon HS, Kim JW, Kim KH, Kim CH, Shim BY, Kim HK. A multicenter
phase II study of belotecan, new camptothecin analogue, in patients with
previously untreated extensive stage disease small cell lung cancer.
Lung Cancer. 2010 Jun;68(3):446-9. Epub 2009 Aug 14. PubMed PMID:
19683359.
6: Kim HS, Kang SB, Seo SS, Han SS, Kim JW, Park NH, Kang SB, Lee HP,
Song YS. Phase I/IIa study of combination chemotherapy with CKD-602 and
cisplatin in patients with recurrent epithelial ovarian cancer. Ann N Y
Acad Sci. 2009 Aug;1171:627-34. PubMed PMID: 19723113.
7: Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H,
Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK.
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in
patients with advanced malignancies. Clin Pharmacol Ther. 2009
Nov;86(5):519-26. Epub 2009 Aug 12. PubMed PMID: 19675541.
8: Jin QR, Shim WS, Choi MK, Tian GY, Song IS, Yang SG, Kim DD, Chung
SJ, Shim CK. Decreased urinary secretion of belotecan in folic
acid-induced acute renal failure rats due to down-regulation of Oat1 and
Bcrp. Xenobiotica. 2009 Oct;39(10):711-21. PubMed PMID: 19552531.
9: Kim YY, Park CK, Kim SK, Phi JH, Kim JH, Kim CY, Wang KC, Cho BK.
CKD-602, a camptothecin derivative, inhibits proliferation and induces
apoptosis in glioma cell lines. Oncol Rep. 2009 Jun;21(6):1413-9. PubMed
PMID: 19424618.
10: Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG,
Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK. Phase I and
pharmacokinetic study of pegylated liposomal CKD-602 in patients with
advanced malignancies. Clin Cancer Res. 2009 Feb 15;15(4):1466-72. Epub
2009 Feb 3. Erratum in: Clin Cancer Res. 2009 Apr 15;15(8):2949-50.
PubMed PMID: 19190127.
11: Ok YJ, Myoung H, Kim YK, Lee JH, Kim MJ, Yun PY. Apoptotic effect of
CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines. Oral
Oncol. 2009 Mar;45(3):266-72. Epub 2008 Aug 19. PubMed PMID: 18715816.
12: Lee HP, Seo SS, Ryu SY, Kim JH, Bang YJ, Park SY, Nam JH, Kang SB,
Lee KH, Song YS. Phase II evaluation of CKD-602, a camptothecin analog,
administered on a 5-day schedule to patients with platinum-sensitive or
-resistant ovarian cancer. Gynecol Oncol. 2008 Jun;109(3):359-63. Epub
2008 Apr 10. PubMed PMID: 18405948.
13: Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA,
Tonda ME, Yu NY, Engbers C, Eiseman JL. Plasma, tumor, and tissue
disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal
CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res.
2007 Dec 1;13(23):7217-23. PubMed PMID: 18056203.
14: Lee DH, Kim SW, Bae KS, Hong JS, Suh C, Kang YK, Lee JS. A phase I
and pharmacologic study of belotecan in combination with cisplatin in
patients with previously untreated extensive-stage disease small cell
lung cancer. Clin Cancer Res. 2007 Oct 15;13(20):6182-6. PubMed PMID:
17947485.
15: Lee DH, Kim SW, Suh C, Lee JS, Lee JH, Lee SJ, Ryoo BY, Park K, Kim
JS, Heo DS, Kim NK. Belotecan, new camptothecin analogue, is active in
patients with small-cell lung cancer: results of a multicenter early
phase II study. Ann Oncol. 2008 Jan;19(1):123-7. Epub 2007 Sep 6. PubMed
PMID: 17823384.
16: Yu NY, Conway C, Pena RL, Chen JY. STEALTH liposomal CKD-602, a
topoisomerase I inhibitor, improves the therapeutic index in human tumor
xenograft models. Anticancer Res. 2007 Jul-Aug;27(4B):2541-5. PubMed
PMID: 17695551.
17: Chung MK, Kim CY, Kim JC. Reproductive toxicity evaluation of a new
camptothecin anticancer agent, CKD-602, in pregnant/lactating female
rats and their offspring. Cancer Chemother Pharmacol. 2007
Feb;59(3):383-95. Epub 2006 Aug 1. PubMed PMID: 16896929.
18: Chung MK, Han SS, Kim JC. Evaluation of the toxic potentials of a
new camptothecin anticancer agent CKD-602 on fertility and early
embryonic development in rats. Regul Toxicol Pharmacol. 2006
Aug;45(3):273-81. Epub 2006 Jun 30. PubMed PMID: 16814440.
19: Chung MK, Kim JC, Han SS. Embryotoxic effects of CKD-602, a new
camptothecin anticancer agent, in rats. Reprod Toxicol. 2005
May-Jun;20(1):165-73. PubMed PMID: 15808800.
20: Kim JC, Shin DH, Park SH, Park SC, Kim YB, Kim HC, Cha SW, Cho KH,
Kang BH, Chung MK. 4-Week repeated intravenous dose toxicity study of a
new camptothecin anticancer agent CKD-602 in dogs. Food Chem Toxicol.
2005 May;43(5):699-706. PubMed PMID: 15778009.
21: Chung MK, Kim JC, Han SS. Effects of CKD-602, a new camptothecin
anticancer agent, on pregnant does and embryo-fetal development in
rabbits. Drug Chem Toxicol. 2005;28(1):35-49. PubMed PMID: 15720034.
22: Kim JC, Shin DH, Kim SH, Kim JK, Park SC, Son WC, Lee HS, Suh JE,
Kim CY, Ha CS, Chung MK. Subacute toxicity evaluation of a new
camptothecin anticancer agent CKD-602 administered by intravenous
injection to rats. Regul Toxicol Pharmacol. 2004 Dec;40(3):356-69.
PubMed PMID: 15546689.
23: Crul M. CKD-602. Chong Kun Dang. Curr Opin Investig Drugs. 2003
Dec;4(12):1455-9. Review. PubMed PMID: 14763132.
24: Kim EJ, Lee RK, Suh JE, Han SS, Kim JK. Safety pharmacology of
CKD-602, a novel anticancer agent. Arzneimittelforschung.
2003;53(4):272-9. PubMed PMID: 12785124.
25: Cho JY, Seo HB, Yu KS, Bae KS, Yi SY, Jang IJ, Shin SG. Simple and
sensitive determination of the new antitumor drug CKD-602 in human
plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed
Life Sci. 2003 Jan 25;784(1):25-31. PubMed PMID: 12504179.
26: Park IS, Ahn MR, Suh SK, Choi HS, Sohn SJ, Yang JS, Yoo TM, Kuh HJ.
In vitro pharmacodynamics of CKD-602 in HT-29 cells. Arch Pharm Res.
2002 Oct;25(5):718-23. Erratum in: Arch Pharm Res. 2002 Dec;25(6):989.
PubMed PMID: 12433211.
27: Kim JH, Lee SK, Lim JL, Shin HJ, Hong CI. Preformulation studies of
a novel camptothecin anticancer agent, CKD-602: physicochemical
characterization and hydrolytic equilibrium kinetics. Int J Pharm. 2002
Jun 4;239(1-2):207-11. PubMed PMID: 12052706.
28: Lee JH, Lee JM, Lim KH, Kim JK, Ahn SK, Bang YJ, Hong CI.
Preclinical and phase I clinical studies with Ckd-602, a novel
camptothecin derivative. Ann N Y Acad Sci. 2000;922:324-5. PubMed PMID:
11193913.
29: Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, Jew SS, Park JG,
Hong CI. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin,
CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res. 1998
Oct;21(5):581-90. PubMed PMID: 9875499.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
